92 filings
6-K
ADXN
Addex Therapeutics Ltd
6 Jun 24
Current report (foreign)
6:00am
6-K
ADXN
Addex Therapeutics Ltd
5 Jun 24
Addex Convenes Annual General Meeting 2024
6:05am
6-K
ADXN
Addex Therapeutics Ltd
29 Apr 24
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
6:05am
6-K
ADXN
Addex Therapeutics Ltd
18 Apr 24
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
6:05am
6-K
ADXN
Addex Therapeutics Ltd
3 Apr 24
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
6:05am
6-K
fiufrsq6
30 Jan 24
Current report (foreign)
4:58pm
6-K/A
kblo9s kwbdel
21 Dec 23
Current report (foreign) (amended)
6:00am
6-K
b5hgn
20 Dec 23
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
6:05am
6-K
m2pn88goy6dexjlq3nq
14 Dec 23
Addex Creates Treasury Shares
6:05am
6-K
b5u3vhkrac7l
29 Nov 23
Current report (foreign)
6:00am
6-K
sumwq kfm5n
28 Nov 23
Addex Convenes Extraordinary General Meeting
6:05am
6-K
vmhv6a5a kc4f
14 Nov 23
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
6:05am
6-K
k2ieum55stc98lki
8 Nov 23
Current report (foreign)
6:05am
6-K
kks6469
20 Oct 23
Addex Completes ADS Ratio Change
6:05am
6-K
jk24tts9jej
6 Oct 23
Addex Announces Plan to Implement ADS Ratio Change
4:00pm
6-K
jxfy9hky2 5ulxk
20 Sep 23
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
6:05am
6-K
y9hapmb0
5 Sep 23
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
6:10am
6-K
vl1i 13kdm298lng
5 Sep 23
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
6:10am
6-K
dn8db83dm rn
10 Aug 23
Current report (foreign)
6:31am
6-K
gpv24l0 rf7ec8oyhhq
3 Aug 23
Current report (foreign)
6:05am